Alnylam Pharmaceuticals (ALNY) CSO reports PSU vesting and stock sales
Rhea-AI Filing Summary
Alnylam Pharmaceuticals CSO & EVP, Head of Research Kevin Fitzgerald reported multiple equity transactions in the company’s common stock. On January 11, 2026, he received 3,800 shares at $0.0 per share upon vesting of a performance-based stock unit grant tied to the company publicly reporting $2.5 billion in annual net product revenue under GAAP, as determined by the board’s People, Culture and Compensation Committee.
On January 12, 2026, shares were automatically sold on his behalf under a mandatory sell-to-cover provision to satisfy minimum tax withholding, including blocks such as 39 shares at $353.95. On January 13, 2026, he executed additional open-market sales under a Rule 10b5-1(c) trading plan adopted on August 14, 2025, including 197 shares at $367.52 and 562 shares at $368.76. After these transactions, he held 21,264 shares directly and 537 shares indirectly through a managed account.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 197 | $367.52 | $72K |
| Sale | Common Stock | 562 | $368.76 | $207K |
| Sale | Common Stock | 644 | $370.00 | $238K |
| Sale | Common Stock | 485 | $371.24 | $180K |
| Sale | Common Stock | 280 | $372.93 | $104K |
| Sale | Common Stock | 122 | $374.33 | $46K |
| Sale | Common Stock | 39 | $353.95 | $14K |
| Sale | Common Stock | 42 | $355.16 | $15K |
| Sale | Common Stock | 41 | $356.09 | $15K |
| Sale | Common Stock | 96 | $357.17 | $34K |
| Sale | Common Stock | 123 | $358.18 | $44K |
| Sale | Common Stock | 85 | $359.14 | $31K |
| Sale | Common Stock | 155 | $360.22 | $56K |
| Sale | Common Stock | 98 | $361.45 | $35K |
| Sale | Common Stock | 73 | $362.38 | $26K |
| Sale | Common Stock | 47 | $363.55 | $17K |
| Sale | Common Stock | 199 | $364.83 | $73K |
| Sale | Common Stock | 220 | $365.56 | $80K |
| Sale | Common Stock | 50 | $366.41 | $18K |
| Sale | Common Stock | 41 | $367.40 | $15K |
| Sale | Common Stock | 92 | $368.62 | $34K |
| Sale | Common Stock | 40 | $369.48 | $15K |
| Sale | Common Stock | 19 | $370.87 | $7K |
| Sale | Common Stock | 2 | $372.46 | $744.92 |
| Sale | Common Stock | 14 | $374.44 | $5K |
| Sale | Common Stock | 19 | $375.65 | $7K |
| Sale | Common Stock | 15 | $377.82 | $6K |
| Grant/Award | Common Stock | 3,800 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting $2.5 billion in annual net product revenue in accordance with GAAP, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors on January 11, 2026. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $353.53 to $354.41. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $354.54 to $355.53. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.62 to $356.61. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.63 to $357.63. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $357.68 to $358.68. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $358.69 to $359.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $359.79 to $360.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $360.90 to $361.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $361.93 to $362.92. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $362.99 to $363.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $364.00 to $365.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $365.01 to $366.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $366.03 to $366.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $367.04 to $368.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $368.09 to $369.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $369.13 to $369.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $370.43 to $371.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $372.35 to $372.50. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $374.08 to $374.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $367.18 to $367.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $368.25 to $369.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $369.36 to $370.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $370.52 to $371.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $372.70 to $373.11. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $374.28 to $374.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
FAQ
What insider activity did ALNY CSO Kevin Fitzgerald report on this Form 4?
Kevin Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals (ALNY), reported receipt of performance-based stock units that vested into 3,800 common shares on January 11, 2026, followed by multiple sales of common stock on January 12–13, 2026.
Did Kevin Fitzgerald use a Rule 10b5-1 trading plan for any ALNY stock sales?
Yes. Footnote (22) states that the January 13, 2026 sales, including trades such as 197 shares at $367.52 and 562 shares at $368.76, were executed under a Rule 10b5-1(c) trading plan adopted on August 14, 2025.